The US Oncology Network | Strategic Alliance Partners

Bradley J. Monk, MD, FACS, discusses the emergence and utility of NaPi2b as a target in ovarian cancer.

Practices using Oncology Care Model improved patient care while saving Medicare $197 million.

The accelerated approval of the tissue factor–directed antibody and microtubule inhibitor tisotumab vedotin-tftv bolsters the treatment portfolio for patients with recurrent metastatic cervical cancer.

A marked reduction in hospitalizations and emergency department visits are key metrics for value-based care programs. Quality improvement processes and electronic patient management systems may give practices a way to fully embrace these programs and remain mindful of cost while ensuring that patients receive high-quality care.

Ontada, a McKesson business focused on real-world data and evidence, clinical education and provider technology, announced the launch of Health Outcomes Powered by Evidence Studies.

The US Oncology Network, the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, announced today that it has appointed Jason Hammonds as its new president.

Dana Chase, MD, FACOG, discusses the importance of utilizing genetic testing to guide treatment decisions for patients with ovarian cancer.

Practice-validating trials in cervical cancer, endometrial cancer, and ovarian cancer were the focus of the 2021 ASCO Annual Meeting in gynecologic oncology, each carrying relevant implications on extended therapy, surveillance, and biomarker testing.

Practices participating in the Oncology Care Model, an experimental payment model developed by the Center for Medicare and Medicaid Innovation, are incentivized to improve patient experiences and outcomes by providing enhanced services and care while bending the total cost curve.

The US Oncology Network, the largest organization of its kind dedicated to advancing local cancer care and better patient outcomes, continues to expand its reach into local communities while broadening its surgical expertise with the addition of physicians from Texas Colon & Rectal Specialists, a large colorectal practice in North Texas, as a part of Texas Oncology, a practice in The Network.

Community-based practices in The Network advance value-based care by significantly reducing costs while enhancing care.

Bradley J. Monk, MD, FACS, FACOG, discusses the FDA approval of bevacizumab and other novel agents in cervical cancer.

Robert L. Coleman, MD, FACOG, FACS, discusses recent advances made in the treatment of patients with ovarian cancer and remaining questions regarding the role of immunotherapy.

Christopher A. Yasenchak, MD, discusses findings from the phase 2 trial with brentuximab vedotin and nivolumab in patients with newly diagnosed classical Hodgkin lymphoma.

The US Oncology Network (The Network) has named prominent cancer researcher Robert L. Coleman, MD, FACOG, FACS, as its new Chief Scientific Officer.

Neelima Denduluri, MD, shares treatment approaches in patients with early-stage hormone receptor-positive, HER2-negative breast cancer.

Jeff Sharman, MD, discusses the question of BTK inhibitors in treating patients with chronic lymphocytic leukemia.

Jeff Sharman, MD, discusses the design of the phase III ELEVATE-TN trial in patients with previously untreated chronic lymphocytic leukemia.

Top researchers will present abstracts on latest clinical research advancing cancer treatment options.

Robert M. Rifkin, MD, attending physician, Rocky Mountain Cancer Centers, research lead, Multiple Myeloma, The US Oncology Network, discusses a trial looking at split dosing of daratumumab in myeloma.

The US Oncology Network has announced the results of the 2017 Merit-based Incentive Payment System for its affiliated practices.

Pressure to reduce costs associated with biologics is one of the forces driving the rapid expansion of biosimilars, which are biological drugs that are very similar to already approved reference biologics in terms of potency, safety, and efficacy.

Number One Rankings in 10 Key Performance Areas Reinforce McKesson Specialty Health’s Leading Position in the Oncology and Hematology Market

McKesson’s total solution streamlines MIPS reporting and provides access to custom quality measures, optimizing MIPS performance for community-based oncology practices

Consultants in Medical Oncology and Hematology (CMOH) has joined The US Oncology Network (The Network).

Providers using iKnowMed certified EHR technology are eligible for Quality Performance bonus points under Merit-based Incentive Payment System.

Southern Cancer Center, a premier oncology clinic in Alabama and a practice in The US Oncology Network, is the first site in the world to open enrollment for a new clinical trial for newly diagnosed kidney cancer patients.

Expanded agreement enhances Value Pathways, providing physicians access to the most recent evidence available for five additional disease states.

Practice with largest infusion treatment center in Delaware gains access to world-class treatments and enhances its cutting-edge research program.

Joyce A. O’Shaughnessy, MD, addresses the key issues in breast cancer discussed at the 2017 OncLive® State of the Science Summit on Treatment of Metastatic Breast Cancer and shared her expert insight on where triple-negative breast cancer treatment is headed based on recent findings.